1
|
Abdelmegid MAKF, Hanna MEF, Demitry SR, Abdelhafez MAH. Coronary artery disease severity and risk stratification of patients with non ST-elevation acute coronary syndrome using CHA 2DS 2-VASc-HSF score. BMC Cardiovasc Disord 2024; 24:263. [PMID: 38773382 PMCID: PMC11106988 DOI: 10.1186/s12872-024-03929-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2023] [Accepted: 05/08/2024] [Indexed: 05/23/2024] Open
Abstract
BACKGROUND Risk stratification assessment of patients with non-ST elevation acute coronary syndrome (NSTE ACS) plays an important role in optimal management and defines the patient's prognosis. This study aimed to evaluate the ability of CHA2DS2-VASc-HSF score (comprising of the components of the CHA2DS2-VASc score with a male instead of female sex category, hyperlipidemia, smoking, and family history of coronary artery disease respectively) to predict the severity and complexity of CAD and its efficacy in stratification for major adverse cardiovascular events (MACE) in patients with NSTE ACS without known atrial fibrillation. METHODS This study included 200 patients (males 72.5%, mean age 55.8 ± 10.1 years) who were admitted with NSTE ACS. CHA2DS2-VASC-HSF score was calculated on admission. Patients were classified into three groups according to their CHA2DS2-VASC-HSF score: low score group (< 2; 29 patients), intermediate score group (2-4; 83 patients), and high score group (≥ 5; 88 patients). Coronary angiography was conducted and the Syntax score (SS) was calculated. Clinical follow-up at 6 months of admission for the development of MACE was recorded. RESULTS SS was significantly high in the high CHA2DS2-VASc-HSF score group compared with low and intermediate score groups. CHA2DS2-VASc-HSF score had a significant positive strong correlation with syntax score (r = 0.64, P < 0.001). Smoking, vascular disease, hyperlipidemia, and CHA2DS2-VASc-HSF score were independent predictors of high SS. For the prediction of severe and complex CAD, CHA2DS2-VASc-HSF score had a good predictive power at a cut-off value ≥ 5 with a sensitivity of 86% and specificity of 65%. Hypertension, vascular disease, high SS, and CHA2DS2-VASc-HSF score were independent predictors of MACE. CHA2DS2-VASC-HSF score ≥ 4 was identified as an effective cut-off point for the development of MACE with 94% sensitivity and 70% specificity. CONCLUSIONS CHA2DS2-VASC-HSF score is proposed to be a simple bedside score that could be used for the prediction of the severity and complexity of CAD as well as a risk stratification tool for the development of MACE in NSTE ACS patients.
Collapse
Affiliation(s)
| | | | - Salwa R Demitry
- Cardiovascular Medicine Department, Assiut University Heart Hospital, Assiut University, Assiut, 71526, Egypt
| | | |
Collapse
|
2
|
Risk stratification of cardiovascular complications using CHA 2DS 2-VASc and CHADS 2 scores in chronic atherosclerotic cardiovascular disease. Int J Cardiol 2021; 337:9-15. [PMID: 33957178 DOI: 10.1016/j.ijcard.2021.04.067] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/29/2020] [Revised: 04/26/2021] [Accepted: 04/29/2021] [Indexed: 11/22/2022]
Abstract
Background The COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial showed that rivaroxaban plus aspirin reduced major adverse cardiovascular events (MACE) in patients with chronic coronary artery disease (CAD) and/or peripheral artery disease (PAD). We explored whether CHA2DS2-VASc or CHADS2 scores, well-validated tools for assessing risk of thromboembolic events in atrial fibrillation, can identify vascular patients at highest risk of recurrent events who may derive greatest benefits of treatment. Methods Predictive accuracies of the CHA2DS2-VASc and CHADS2 scores for MACE, were assessed in this analysis of the COMPASS trial. Kaplan-Meier estimates of cumulative risk were used to compare the effects of rivaroxaban plus aspirin (n = 9152) with aspirin alone (n = 9126) according to risk scores. Results High CHA2DS2-VASc (6-9) or CHADS2 (3-6) scores were associated with over three times greater absolute risk of MACE compared with CHA2DS2-VASc score of 1-2 or CHADS2 score of 0. The effects of rivaroxaban plus aspirin compared with aspirin alone were consistent across CHA2DS2-VASc and CHADS2 score categories for MACE, bleeding and net clinical benefit, with greatest reduction in MACE observed in patients treated for 30 months with highest CHADS2 score (3-6) (hazard ratio = 0.67, 95% CI: 0.53-0.86, p = 0.0012, 25 events per 1000 patients prevented). Conclusion The CHA2DS2-VASc and CHADS2 scores can be used in patients with chronic CAD and/or PAD to identify patients who are at highest risk of MACE. Those identified at highest risk by CHADS2 scores had greatest benefit from dual pathway inhibition with rivaroxaban plus aspirin. Clinical Trial Registration: NCT01776424.
Collapse
|
3
|
Abe T, De Allie G, Eyituoyo HO, Abe T, Tobun T, Asotibe JC, Hayes D, Mather P. CHA2DS2-VASc Is Associated With In-Hospital Mortality in Patients With Infective Endocarditis: A Cross-Sectional Cohort Study. Cureus 2020; 12:e11620. [PMID: 33364135 PMCID: PMC7752800 DOI: 10.7759/cureus.11620] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
Background and objective The CHA2DS2-VASc score is a stroke risk stratification tool that is used in patients with atrial fibrillation (AF). Most of its clinical variables have been associated with poor outcomes in patients with infective endocarditis (IE). In this study, we aimed to determine its utility in predicting outcomes in IE patients. Methods We included 35,570 patients with IE from the National Inpatient Sample (NIS), 2009-2012. The CHA2DS2-VASc score was calculated for each patient. Hierarchical logistic regression was used to estimate the adjusted odds ratio for in-hospital mortality for CHA2DS2-VASc scores from 1 to 9, using a score of 0 as the reference score. All clinical characteristics were defined using the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes. Results The mean age of the sample was 57.81 ±14 years. Higher CHA2DS2-VASc scores were associated with increased mortality, and the scores among the sample ranged from 0 for 8.1% to 8 for 21.7%. In the hierarchical logistic regression, after adjusting for age, sex, and relevant comorbidities, as the score increased, so did the odds for overall mortality. Conclusion In patients with IE, the CHA2DS2-VASc score may serve as a risk assessment tool with which to predict outcomes. Further studies are needed to replicate these findings.
Collapse
Affiliation(s)
- Temidayo Abe
- Internal Medicine, Morehouse School of Medicine, Atlanta, USA
| | | | - Harry O Eyituoyo
- Internal Medicine/Community Medicine, Mercer University School of Medicine, Macon, USA
| | - Tolulope Abe
- Internal Medicine, All Saints University School of Medicine, Roseau, DMA
| | - Temitope Tobun
- Internal Medicine, All Saints University School of Medicine, Roseau, DMA
| | | | - Dolphurs Hayes
- Internal Medicine, Morehouse School of Medicine, Atlanta, USA.,Department of Medicine, Morehouse School of Medicine, Atlanta, USA
| | - Paul Mather
- Department of Cardiovascular Disease, Perelman School of Medicine, Philadelphia, USA
| |
Collapse
|
4
|
Ciftci O, Yilmaz KC, Karacaglar E, Yilmaz M, Ozin B, Muderrisoglu IH. The Novel CHA 2DS 2-VASC-FSH Score is Predictive of Severe Coronary Artery Disease on Coronary Angiography in Patients with Atrial Fibrillation and Unstable Symptoms. Eurasian J Med 2019; 51:165-171. [PMID: 31258358 DOI: 10.5152/eurasianjmed.2019.18342] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Objective AF may create confusion about the presence of severe or unstable coronary artery disease in cases with unstable symptoms. Novel scores and markers are needed to determine severe coronary artery disease in such patients. We aimed to test the newly developed CHA2DS2-VASc-FSH score, developed by adding family history for coronary artery disease, hyperlipidemia, and smoking to the original CHA2DS2-VASc score, in the prediction of severe CAD in patients with AF and unstable symptoms. Materials and Methods We retrospectively analyzed 72 patients presenting to Başkent Universtiy School of Medicine Hospital between April 2011 and January 2016. The CHA2DS2VASc-FSH score was assessed for the prediction of severe CAD. Results Seventy-two patients aged 65.7±11.2 years were enrolled. Thirty-five (48.6%) patients had severe CAD and 11 (15.3%) had unstable CAD. patients with severe coronary artery disease had a significantly greater CHA2DS2VASC-FSH score (5 (1-8) vs 3(0-7); p<0.05). The CHA2DS2VASC-FSH score independently predicted severe CAD, with a CHA2DS2VASc-FSH score of 3 or greater having a sensitivity of 77.1% and a specificity of 56.8% for severe CAD. Conclusion Among patients with AF and unstable symptoms, the CHA2DS2VASc-FSH score independently predicts severe CAD.
Collapse
Affiliation(s)
- Orcun Ciftci
- Department of Cardiology, Başkent University School of Medicine, Ankara Hospital, Ankara, Turkey
| | - Kerem Can Yilmaz
- Department of Cardiology, Başkent University School of Medicine, Ankara Hospital, Ankara, Turkey
| | - Emir Karacaglar
- Department of Cardiology, Başkent University School of Medicine, Ankara Hospital, Ankara, Turkey
| | - Mustafa Yilmaz
- Department of Cardiology, Başkent University School of Medicine, Adana Hospital, Adana, Turkey
| | - Bulent Ozin
- Department of Cardiology, Başkent University School of Medicine, Ankara Hospital, Ankara, Turkey
| | | |
Collapse
|
5
|
Ashoori A, Pourhosseini H, Ghodsi S, Salarifar M, Nematipour E, Alidoosti M, Haji-Zeinali AM, Nozari Y, Amirzadegan A, Aghajani H, Jalali A, Hosseini Z, Jenab Y, Geraiely B, Omidi N. CHA2DS2-VASc Score as an Independent Predictor of Suboptimal Reperfusion and Short-Term Mortality after Primary PCI in Patients with Acute ST Segment Elevation Myocardial Infarction. ACTA ACUST UNITED AC 2019; 55:medicina55020035. [PMID: 30717292 PMCID: PMC6409514 DOI: 10.3390/medicina55020035] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2019] [Revised: 01/18/2019] [Accepted: 01/22/2019] [Indexed: 01/09/2023]
Abstract
Background and objectives: We aimed to demonstrate the clinical utility of CHA2DS2-VASc score in risk assessment of patients with STEMI regarding adverse clinical outcomes particularly no-reflow phenomenon. Materials and Methods: We designed a retrospective cohort study using the data of Tehran Heart Center registry for acute coronary syndrome. The study included 1331 consecutive patients with STEMI who underwent primary angioplasty. Patients were divided into two groups according to low and high CHA2DS2-VASc score. Angiographic results of reperfusion were inspected to evaluate the association of high CHA2DS2-VASc score and the likelihood of suboptimal TIMI flow. The secondary endpoint of the study was short-term in-hospital mortality of all cause. Results: The present study confirmed that CHA2DS2-VASc model enables us to determine the risk of no-reflow and all-cause in-hospital mortality independently. Odds ratios were 1.59 (1.30–2.25) and 1.60 (1.17–2.19), respectively. Moreover, BMI, high thrombus grade, and cardiogenic shock were predictors of failed reperfusion (odds were 1.07 (1.01–1.35), 1.59 (1.28–1.76), and 8.65 (3.76–24.46), respectively). We showed that using a cut off value of ≥ two in CHA2DS2-VASc model provides a sensitivity of 69.7% and specificity of 64.4% for discrimination of increased mortality hazards. Area under the curve: 0.72 with 95% CI (0.62–0.81). Conclusions: Calculation of CHA2DS2-VASc score applied as a simple risk stratification tool before primary PCI affords great predictive power. Furthermore, incremental values are obtained by using both CHA2DS2-VASc and no-reflow regarding mortality risk assessment.
Collapse
Affiliation(s)
- Ammar Ashoori
- Tehran Heart Center, Tehran University of Medical Sciences, Tehran 1411713138, Iran.
| | | | - Saeed Ghodsi
- Tehran Heart Center, Tehran University of Medical Sciences, Tehran 1411713138, Iran.
| | - Mojtaba Salarifar
- Tehran Heart Center, Tehran University of Medical Sciences, Tehran 1411713138, Iran.
| | - Ebrahim Nematipour
- Tehran Heart Center, Tehran University of Medical Sciences, Tehran 1411713138, Iran.
| | - Mohammad Alidoosti
- Tehran Heart Center, Tehran University of Medical Sciences, Tehran 1411713138, Iran.
| | | | - Yones Nozari
- Tehran Heart Center, Tehran University of Medical Sciences, Tehran 1411713138, Iran.
| | - Alireza Amirzadegan
- Tehran Heart Center, Tehran University of Medical Sciences, Tehran 1411713138, Iran.
| | - Hassan Aghajani
- Tehran Heart Center, Tehran University of Medical Sciences, Tehran 1411713138, Iran.
| | - Arash Jalali
- Tehran Heart Center, Tehran University of Medical Sciences, Tehran 1411713138, Iran.
| | - Zahra Hosseini
- Department of Cardiology, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran 1411713138, Iran.
| | - Yaser Jenab
- Tehran Heart Center, Tehran University of Medical Sciences, Tehran 1411713138, Iran.
| | - Babak Geraiely
- Tehran Heart Center, Tehran University of Medical Sciences, Tehran 1411713138, Iran.
| | - Negar Omidi
- Tehran Heart Center, Tehran University of Medical Sciences, Tehran 1411713138, Iran.
| |
Collapse
|
6
|
Ogunbayo GO, Pecha R, Misumida N, Hillerson D, Elbadawi A, Abdel-Latif A, Elayi CS, Messerli AW, Smyth SS. Relation of CHA 2DS 2VASC Score With Hemorrhagic Stroke and Mortality in Patients Undergoing Fibrinolytic Therapy for ST Elevation Myocardial Infarction. Am J Cardiol 2019; 123:212-217. [PMID: 30415795 DOI: 10.1016/j.amjcard.2018.10.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/13/2018] [Revised: 09/27/2018] [Accepted: 10/02/2018] [Indexed: 12/18/2022]
Abstract
Hemorrhagic stroke (HS) is a feared complication of Fibrinolytic therapy (FT). Risk assessment scores may help in risk stratification to reduce this complication. Patients (admissions) ≥18 years with a primary diagnosis of ST-elevation myocardial infarction (STEMI) who received systemic thrombolysis were extracted from Nationwide Inpatient Sample database and stratified and compared based on CHA2DS2VASC score 0 to 3, 4 to 6, and 7 to 9 as low, intermediate and high risk, respectively. The primary outcomes of interest were HS and mortality. We performed logistic regression analysis with a composite of HS and mortality as the primary end point. Of the 917,307 admissions with a primary diagnosis of STEMI, 39,579 (4.3%) underwent FT. The median score was 3 (interquartile range 1 to 5). The rate of HS significantly increased in the risk category compared with the low and intermediate groups (0.5% and 0.6% vs 4.1%; p <0.001). Mortality increased with increasing risk category (3.8% vs 10.5% vs 20.7%; p <0.001). Compared with the low-risk group patients in the intermediate (odds ratio 2.11 95% confidence interval [CI] 1.56 to 2.85; p <0.001) and high risk groups (odds ratio 3.47 95% CI 1.68 to 7.2; p <0.001) were more likely to experience the composite end point of HS or inpatient mortality. CHA2DS2VASC score performed better at predicting mortality (area under curve 0.67, 95% CI 0.64 to 0.7; p = 0.014) than HS (area under curve 0.6 95% CI 0.52 to 0.69; p = 0.021). In conclusion, patients with high CHA2DS2VASC score (7 to 9) are at a higher risk of hemorrhagic stroke and death after FT for STEMI. CHA2DS2VASC score performed better at predicting mortality than hemorrhagic stroke in this cohort.
Collapse
|